AR020054A1 - COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS - Google Patents

COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS

Info

Publication number
AR020054A1
AR020054A1 ARP990100656A ARP990100656A AR020054A1 AR 020054 A1 AR020054 A1 AR 020054A1 AR P990100656 A ARP990100656 A AR P990100656A AR P990100656 A ARP990100656 A AR P990100656A AR 020054 A1 AR020054 A1 AR 020054A1
Authority
AR
Argentina
Prior art keywords
adenovirus
composition understanding
virus
virus preparations
composition
Prior art date
Application number
ARP990100656A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR020054A1 publication Critical patent/AR020054A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composicion que contiene virus en una formulacion que contiene un polihidroxi hidrocarburo regulada para mantener un ph en el intervalo de aproximadamente7 a aproximadamente 8,5 a una temperatura en el orden de aproximadamente 2sC a 27sC; preparadosde virus concentrado y purificado y métodos para concentrar ypurificar dichos preparados de virus. Estos virus se utilizan para terapia génica.
ARP990100656A 1998-02-17 1999-02-23 COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS AR020054A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2446298A 1998-02-17 1998-02-17
US7964398A 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
AR020054A1 true AR020054A1 (es) 2002-04-10

Family

ID=26698472

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990100656A AR020054A1 (es) 1998-02-17 1999-02-23 COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS
ARP070104577A AR063315A2 (es) 1998-02-17 2007-10-16 Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus
ARP070104576A AR063314A2 (es) 1998-02-17 2007-10-16 Metodos para purificar preparados de virus

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP070104577A AR063315A2 (es) 1998-02-17 2007-10-16 Composicion que comprende un virus, y metodos para concentrar y purificar preparados de virus
ARP070104576A AR063314A2 (es) 1998-02-17 2007-10-16 Metodos para purificar preparados de virus

Country Status (24)

Country Link
EP (4) EP1526173B1 (es)
JP (3) JP4358434B2 (es)
KR (5) KR100862169B1 (es)
CN (2) CN100374551C (es)
AR (3) AR020054A1 (es)
AT (3) ATE341614T1 (es)
AU (1) AU757976B2 (es)
BR (1) BR9908015A (es)
CA (2) CA2320419C (es)
CO (1) CO4820440A1 (es)
DE (3) DE69936948T2 (es)
DK (1) DK1054955T3 (es)
ES (2) ES2272053T3 (es)
HU (1) HU226015B1 (es)
ID (1) ID28298A (es)
IL (2) IL137510A0 (es)
MY (1) MY141641A (es)
NO (1) NO20004104L (es)
PE (1) PE20000265A1 (es)
PL (1) PL197747B1 (es)
PT (1) PT1054955E (es)
SK (1) SK11842000A3 (es)
TW (1) TWI232107B (es)
WO (1) WO1999041416A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ES2323991T3 (es) * 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
CA2799545A1 (en) * 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
US20020064860A1 (en) 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
AU2002218535A1 (en) * 2000-12-12 2002-06-24 Japan Tobacco Inc. Pharmaceutical composition containing an active with a hemolytic action and a surfactant
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US20030153065A1 (en) * 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
CA2469721A1 (en) * 2002-01-18 2003-07-31 Schering Aktiengesellschaft Stabilized formulations of adenovirus
ES2329607T3 (es) 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
MX2007007145A (es) 2004-12-13 2007-08-20 Canji Inc Lineas de celulas para produccion de adenovirus con replicacion defectuosa.
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
CN1961961B (zh) * 2005-11-11 2010-05-26 深圳市源兴生物医药科技有限公司 一种药物制剂及其制备方法
DE602006019916D1 (de) 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
ATE539149T1 (de) * 2006-04-20 2012-01-15 Wyeth Llc Reinigungsverfahren zur isolierung von gereinigtem vesikulärem stomatitisvirus aus zellkultur
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
JP5879256B2 (ja) 2009-05-02 2016-03-08 ジェンザイム・コーポレーション 神経変性障害のための遺伝子治療
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
CN103118702A (zh) 2010-09-20 2013-05-22 克鲁塞尔荷兰公司 活动性结核病的治疗性接种
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CN103269716B (zh) 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
MX337348B (es) * 2011-04-29 2016-02-29 Oncolytics Biotech Inc Metodos para purificar virus utilizando cromatografia de permeacion en gel.
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
SG11201609908VA (en) * 2014-05-28 2016-12-29 Agency Science Tech & Res Virus reduction method
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) * 2017-07-24 2019-01-31 Ella Foundation VACCINE AGAINST FOOT AND MOUTH DISEASE
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
CN113164583A (zh) 2018-11-13 2021-07-23 扬森疫苗与预防公司 稳定的融合前rsv f蛋白
US20220267796A1 (en) * 2019-06-28 2022-08-25 Takeda Pharmaceutical Company Limited Adeno-associated virus purification methods
WO2021155323A1 (en) 2020-01-31 2021-08-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines
KR20230013021A (ko) * 2020-03-19 2023-01-26 트리젤 엘티디. 온도-반응성 바이러스 저장 시스템
EP4294436A1 (en) 2021-02-19 2023-12-27 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv fb fantigens
CN115989321B (zh) * 2021-08-17 2026-03-24 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE299213C (es) *
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
GB1575155A (en) * 1978-04-11 1980-09-17 Merck & Co Inc Vaccine stabilizer
BE866330A (fr) * 1978-04-25 1978-10-25 Merck & Co Inc Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
DD299213A7 (de) * 1988-05-04 1992-04-09 Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) * 1988-05-06 1991-11-14 Saechsisches Serumwerk Gmbh Dresden, Immobilisiertes immunologisch aktives reagens
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
KR100368686B1 (ko) * 1994-12-29 2003-12-01 주식회사 엘지생명과학 수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) * 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

Also Published As

Publication number Publication date
AR063315A2 (es) 2009-01-21
HK1073481A1 (en) 2005-10-07
PL197747B1 (pl) 2008-04-30
ID28298A (id) 2001-05-10
AU757976B2 (en) 2003-03-13
NO20004104D0 (no) 2000-08-16
EP1526174B1 (en) 2007-08-22
CA2320419A1 (en) 1999-08-19
DE69942708D1 (de) 2010-10-07
HUP0100670A3 (en) 2003-10-28
EP1054955A2 (en) 2000-11-29
EP1741777A1 (en) 2007-01-10
CN1297478A (zh) 2001-05-30
EP1054955B1 (en) 2006-10-04
KR20090038927A (ko) 2009-04-21
WO1999041416A2 (en) 1999-08-19
DE69933433T2 (de) 2007-08-23
EP1526174A3 (en) 2005-08-31
DE69933433D1 (de) 2006-11-16
EP1526174A2 (en) 2005-04-27
KR100862169B1 (ko) 2008-10-09
EP1526173A3 (en) 2005-08-10
KR101018992B1 (ko) 2011-03-07
CN100374551C (zh) 2008-03-12
AR063314A2 (es) 2009-01-21
JP4358434B2 (ja) 2009-11-04
ES2272053T3 (es) 2007-04-16
HU226015B1 (en) 2008-02-28
DK1054955T3 (da) 2007-01-15
CN101164623A (zh) 2008-04-23
JP2006166925A (ja) 2006-06-29
JP2010213727A (ja) 2010-09-30
HUP0100670A2 (hu) 2001-06-28
KR20090127947A (ko) 2009-12-14
SK11842000A3 (sk) 2001-05-10
ES2290613T3 (es) 2008-02-16
ATE371020T1 (de) 2007-09-15
ATE478945T1 (de) 2010-09-15
TWI232107B (en) 2005-05-11
WO1999041416A3 (en) 1999-11-18
EP1741777B1 (en) 2010-08-25
KR100912362B1 (ko) 2009-08-19
CA2723040A1 (en) 1999-08-19
NO20004104L (no) 2000-10-17
KR20010072547A (ko) 2001-07-31
AU2653899A (en) 1999-08-30
KR20080065615A (ko) 2008-07-14
DE69936948D1 (de) 2007-10-04
HK1097413A1 (en) 2007-06-22
DE69936948T2 (de) 2008-05-15
KR20080065614A (ko) 2008-07-14
CN101164623B (zh) 2012-11-14
MY141641A (en) 2010-05-31
KR100918187B1 (ko) 2009-09-22
ATE341614T1 (de) 2006-10-15
BR9908015A (pt) 2001-04-24
IL137510A (en) 2012-10-31
JP2002503484A (ja) 2002-02-05
PL342847A1 (en) 2001-07-16
PE20000265A1 (es) 2000-04-25
EP1526173A2 (en) 2005-04-27
PT1054955E (pt) 2007-01-31
CA2320419C (en) 2011-02-08
KR100991683B1 (ko) 2010-11-04
CO4820440A1 (es) 1999-07-28
EP1526173B1 (en) 2012-11-21
IL137510A0 (en) 2001-07-24
HK1028416A1 (en) 2001-02-16

Similar Documents

Publication Publication Date Title
BR9908015A (pt) Composições que compreendem vìrus e métodos para concentração de preparações de vìrus
GB2199328B (en) Use of a 5' untranslated leader sequence of an rna virus to enhance translation
NO20003698D0 (no) Orale sammensetninger
DK0973735T3 (da) Polyaromatiske antivirale præparater
DE59310337D1 (de) 2,4-Dioxo-imidazolidin-Derivate
DE69938255D1 (de) Verfahren und zusammensetzung zur konservierung von adenoviren
BR0010220A (pt) Compostos de pirimidinona
TR199902626T2 (xx) Enflamasyon tedavisi i�in ikameli benzopiran t�revleri.
CO5050303A1 (es) Composicion farmaceutica para tratar infecciones virales y metodos para su preparacion su aplicacion
FI941964L (fi) Pitkäketjuiset alfa-asetyleenialkoholit hydrosilylointireaktion estoaineina ja niiden käyttäminen stabiilien, kovettuvien silikonikoostumusten valmistukseen
CY1108320T1 (el) Συνεργια προσδεματος apo-2 και αντισωματος anti-her-2
PL330407A1 (en) Substituted cyclopentane compounds useful as neuraminidaze inhibitors
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
DK1016711T3 (da) Fremgangsmåde til inaktivering af kappeklædte virus i et viruspræparat med adenovirus
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
BR0313455A (pt) modulação "antisense" da expressão de nav1.3
PT1149910E (pt) Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus
BR9807471A (pt) Uso do composto anti-cd40l
ES2130257T3 (es) Nuevos compuestos y conjugados.
ATE309811T1 (de) Analgetikum aus schlangengift
ATE179164T1 (de) Hiv-proteaseinhibitoren
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
BR0111897A (pt) Composto, método para tratar um indivìduo afligido por alguns distúrbios dos sistemas nervosos periférico e central, composição farmacêutica, e, uso de um composto
NO892125D0 (no) Kombinasjon av angiotensin-omvandlende-enzymhemmere med kaliumkanal-modulatorer samt deres anvendelse i legemidler.
EP1163373A4 (en) ANTISENSE MODULATION OF THE CELLULAR INHIBITANT OF THE APOPTOSIS EXPRESSION

Legal Events

Date Code Title Description
FG Grant, registration